Henderson B E, Casagrande J T, Pike M C, Mack T, Rosario I, Duke A
Br J Cancer. 1983 Jun;47(6):749-56. doi: 10.1038/bjc.1983.127.
A case-control study was conducted in Los Angeles County, California, of 127 endometrial cancer cases aged 45 years or less at diagnosis, to investigate the role of fertility, obesity and exogenous oestrogens in the development of the disease in young women. Use of sequential oral contraceptive (SOCs) or oestrogen replacement therapy (ERT) for greater than or equal to 2 years was strongly associated with increased risk of endometrial cancer. After excluding these cases, since the SOC or ERT use was probably the cause of their disease, we were left with 110 case-control pairs for further study. Among these remaining case-control pairs increasing parity was strongly associated with decreased risk (relative risk of 0.12 for women of parity 3 compared to nulliparous women, P less than 0.001). Current weight was associated with increased risk (relative risk of 17.7 for women weighing greater than or equal to 190 lbs compared to women weighing less than 130 lbs, P less than 0.001). Combination oral contraceptive (COC) use was associated with a decreased risk, which decreased with duration of COC use (relative risk of approximately 0.28 at 5 years of use, P less than 0.001), but the estimate of the protective effect was reduced and became statistically non-significant when allowance was made for weight and parity. The protective effect of COC use was only clearly evident in women who had less than 3 live-births and weighed less than 170 lbs. These results provide further support for the "unopposed" oestrogen hypothesis of the aetiology of endometrial cancer.
在加利福尼亚州洛杉矶县开展了一项病例对照研究,研究对象为127例确诊时年龄在45岁及以下的子宫内膜癌患者,旨在调查生育、肥胖和外源性雌激素在年轻女性该疾病发生过程中的作用。使用序贯口服避孕药(SOCs)或雌激素替代疗法(ERT)达2年及以上与子宫内膜癌风险增加密切相关。排除这些病例后,由于其疾病可能是由使用SOC或ERT所致,我们剩下110对病例对照用于进一步研究。在这些剩余的病例对照中,产次增加与风险降低密切相关(与未生育女性相比,产次为3的女性相对风险为0.12,P<0.001)。当前体重与风险增加相关(与体重小于130磅的女性相比,体重大于或等于190磅的女性相对风险为17.7,P<0.001)。使用复方口服避孕药(COC)与风险降低相关,且随着COC使用时间延长风险降低(使用5年时相对风险约为0.28,P<0.001),但在考虑体重和产次后,保护作用的估计值降低且无统计学意义。COC使用的保护作用仅在活产次数少于3次且体重小于170磅的女性中明显。这些结果为子宫内膜癌病因学的“无对抗”雌激素假说提供了进一步支持。